Dr.Anil kumar

Medical Oncology and Hematology

[Dr.Anil kumar @anianeel]

@DrRishabhOnco Interesting times ahead in triple negative breast cancer

[Dr.Anil kumar @anianeel]

@nihardesai89 subba rao

[Dr.Anil kumar @anianeel]

@nihardesai89 what's the age. underlying risk factors
to rule out iron deficiency anemia and reactive thrombocytosis before we proceed for a work up of high platlet count

[Dr.Anil kumar @anianeel]

@SanjeevH15 @CMofKarnataka @siddaramaiah @DKShivakumar @KNRajanna_Off @BBMPAdmn @MinOfCooperatn @AmitShah @narendramodi @BSYBJP @hd_kumaraswamy @CaptainRajendra @cskarnataka Agree
Please put the health and family housing society scammers behind jail

[Dr.Anil kumar @anianeel]

@punitmeh @Tejasvi_Surya @BSBommai @AmitShah Health and family welfare house building Cooperative society taking public money for ride and still culprits are roaming freely and geting ready to contest elections
Where is justice going?

[Dr.Anil kumar @anianeel]

Interesting .
Good to know and that's good for you

[joanne schlesinger @joqool]

@jillfeldman4 @JackWestMD @n8pennell @DrRoyHerbstYale I did not do@ADAURA trial. 2 yrs 8 months out. Wondering if I should have. Thoughts @jillfeldman4 @JackWestMD

[Oded Rechavi @OdedRechavi]

Putting multiple post-docs on the same project

[Carlos Henrique @CarlosHTonco]

ADAURA wins? For sure OS is the gold standard but with this such impressive DFS adj OSI is really practice changing!!! #ASCO20

[Dr.Anil kumar @anianeel]

Standard of care but not practice changing

[ONCO BRUNO @brunolarvol]

#ASCO20 #ADAURA debate: practice changing?

Opinions from 60 top oncologists:

Team Yes (9 votes): @n8pennell + @glopesmd @jsoriamd @BrendonStilesMD

Team No (10 votes) : @vprasadmdmph + @jackwestmd
@StephenVLiu @BenjaminBesseMD

Full list: https://t.co/tD9mhPV7sK

[Dr.Anil kumar @anianeel]

Confusing

[Vincent Rajkumar @VincentRK]

@brunolarvol @n8pennell @GlopesMd @jsoriamd @BrendonStilesMD @VPrasadMDMPH @JackWestMD @StephenVLiu @BenjaminBesseMD It’s a hard problem. But the truth is either Team A is right. Or Team B is right for the patient in question. We don’t know who’s who. Following EBM principles combined with depth and expertise, usually has a higher probability of winning. But not always.

[Dr.Anil kumar @anianeel]

So it's still not standard of care .
DFS is good but need OS

[gilberto lopes @GlopesMd]

Please note I never said it SHOULD become SOC based on DFS alone. I said it WILL become the ‘de facto’ SOC as physicians and patients won’t want to wait for OS. Not that that’s necessarily right.

[gilberto lopes @GlopesMd]

Please note I never said it SHOULD become SOC based on DFS alone. I said it WILL become the ‘de facto’ SOC as physicians and patients won’t want to wait for OS. Not that that’s necessarily right.

[H. Jack West, MD, FASCO @JackWestMD]

@VincentRK @brunolarvol @n8pennell @GlopesMd @jsoriamd @BrendonStilesMD @VPrasadMDMPH @StephenVLiu @BenjaminBesseMD This was the trial in question.

Nate and I are also writing longer form pieces to hash the issues out more than 280 characters at a time.

[Naoto T Ueno, MD, PhD @teamoncology]

That is what I went through. It is an ultimate form of immunotherapy with a possible cure for advanced hematological malignancies. The risk is high but it is worth it, for me. I am simply talking as a patient, not as a physician. Talk with your doc about this option. #endcancer

[Nathan A. Pennell MD, PhD, FASCO @n8pennell]

@JackWestMD @US_FDA As I get older the whole “approve them all and let people decide” attitude is becoming much less appealing. Too vulnerable to marketing.

[Fred Hutch Cancer Center @fredhutch]

Women with #densebreasts may be getting a new screening modality soon. A new study looked at "abbreviated" MRI for use with dense breast tissue. The mini-MRI takes less than 10 min but is effective at spotting potential cancers. Will it cost less? Read on. https://t.co/MeT29MOXgG

[OncLive.com @OncLive]

Luspatercept has shown efficacy as a treatment of anemia in patients with #myelofibrosis, a disease that is associated with high rates of anemia, explains @AaronGerds of @ClevelandClinic https://t.co/f1nn8yDM9d

[OncLive.com @OncLive]

The @FDAOncology approval is based on findings from the phase III NALA trial, which showed that the combination of neratinib and capecitabine reduced the risk of disease progression or death by 24% compared with lapatinib plus capecitabine #bcsm https://t.co/QRu50t7ix7

[Neelima Denduluri @ndenduluri1]

#KEYNOTE522 - Pembrolizumab improves pCR for #TNBC - thank you to all the patient volunteers! https://t.co/8B2ryherHL @NEJM @BCJoyceO @hmcarthur #bcsm

[Vivek Subbiah, MD @VivekSubbiah]

Artificial intelligence and cancer | Nature Cancer ⁦@NatureCancer⁩ https://t.co/UqXFMdkxyg